Collaborations - Additional Information (Details)								1 Months Ended	12 Months Ended
	Jul. 06, 2021 USD ($) $ / shares shares	Aug. 25, 2020 USD ($) $ / shares shares	Aug. 20, 2020	Jul. 07, 2020 USD ($)	May 09, 2019 USD ($) $ / shares shares	Nov. 01, 2018	Oct. 31, 2017 shares	Jul. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($) shares	Dec. 31, 2019 USD ($) shares
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized									$ 72,832,000	$ 34,034,000	$ 2,934,000
Reverse stock split			1.5949
Research and development									137,017,000	62,105,000	37,158,000
Private Placement | Vertex Pharmaceuticals Incorporated
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of shares, Shares | shares	49,928	676,354
Common stock per share | $ / shares	$ 47.00	$ 20.00
Aggregate proceeds from issuance of private placement	$ 2,300,000	$ 13,500,000						$ 2,300
Sanofi Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment				$ 150,000,000.0
Collaboration agreement transaction price				150,000,000.0
Revenue recognized recorded in deferred revenue									54,300,000	18,800,000
Unsatisfied performance obligation									81,800,000	132,600,000
Cost reimbursement payment received									4,800,000
Unbilled accounts receivable									$ 100,000	900,000
Billed accounts receivable										600,000
Remaining research term of collaboration									2 years 3 months 18 days
Sanofi Agreement | Collaboration Target 1
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price				120,000,000.0
Revenue recognized recorded in deferred revenue									$ 45,500,000	16,700,000
Sanofi Agreement | Collaboration Target 2
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price				30,000,000.0
Revenue recognized recorded in deferred revenue									8,800,000	2,100,000
Sanofi Agreement | Minimum | IRAK4 Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payments				1,000,000,000.0
Commercial milestone payments				400,000,000
Sanofi Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payments				1,480,000,000
Commercial milestone payments				$ 700,000,000.0
Vertex Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized recorded in deferred revenue									18,500,000
Unsatisfied performance obligation									19,200,000	37,700,000
Initial research term of collaboration					4 years
Extended research term of collaboration					1 year
Revenue recognized									$ 18,500,000	15,200,000	2,900,000
Vertex Agreement | Series B-1 Convertible Preferred
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price					$ 55,900,000
Non refundable upfront payment received					$ 50,000,000.0
Issuance of shares, Shares | shares					3,059,695
Common stock per share | $ / shares					$ 6.54
Preferred stock premium					$ 5,900,000
Vertex Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Eligible to receive payments including development, regulatory and commercial milestones					$ 170,000,000.0
Revenue remaining research term									1 year
Compound Collaboration
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Written notice period to terminate collaboration agreement									60 days
Compound Collaboration | Series A Preferred Units
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of shares, Shares | shares							886,305
Reverse stock split						100
Share-based compensation vesting period						3 years
Research and development										$ 300,000	$ 400,000
Vesting of Series A Preferred Stock in connection with collaboration arrangement (Note 5), Shares | shares										166,183	221,579